Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Clinical trials in predementia stages of Alzheimer disease.

Pillai JA, Cummings JL.

Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22. Review.

PMID:
23642580
2.

CAP--advancing the evaluation of preclinical Alzheimer disease treatments.

Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S.

Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29. Review.

PMID:
26416539
3.

Report of the task force on designing clinical trials in early (predementia) AD.

Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B.

Neurology. 2011 Jan 18;76(3):280-6. doi: 10.1212/WNL.0b013e318207b1b9. Epub 2010 Dec 22.

4.
5.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.); Alzheimer Association.

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Review. French.

PMID:
22579080
6.

Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Feldman H, Anand R, Blesa R, Dubois B, Gray J, Homma A, Mohr E, Morris JC, Parys W, Raschig A, Robillard A.

Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:61-4. No abstract available.

PMID:
9305520
7.

Clinical trial design issues in mild to moderate Alzheimer disease.

Knopman DS.

Cogn Behav Neurol. 2008 Dec;21(4):197-201. doi: 10.1097/WNN.0b013e318190cf75. Review.

8.

[Symptomatic therapy of Alzheimer dementia].

Förstl H.

Wien Med Wochenschr. 2002;152(3-4):77-80. German.

PMID:
11925776
9.

Dementia.

Warner J, Butler R.

Clin Evid. 2002 Jun;(7):846-66. Review. No abstract available. Update in: Clin Evid. 2002 Dec;(8):927-50.

PMID:
12230710
10.

Measuring cognitive change in Alzheimer's disease clinical drug trials.

Harrison JE.

J Nutr Health Aging. 2007 Jul-Aug;11(4):327-9. Review.

PMID:
17653492
11.

Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.

Simard M, van Reekum R.

Drugs Aging. 1999 Mar;14(3):197-230. Review.

PMID:
10220105
12.

Maintaining cognitive function in Alzheimer disease: how effective are current treatments?

Tariot PN.

Alzheimer Dis Assoc Disord. 2001 Aug;15 Suppl 1:S26-33.

PMID:
11669506
13.

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.

Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task Force Members.

Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.

PMID:
23809364
14.

Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.

Popp J, Arlt S.

Curr Opin Psychiatry. 2011 Nov;24(6):556-61. doi: 10.1097/YCO.0b013e32834b7b96. Review.

PMID:
21934621
15.

The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.

Doraiswamy PM, Kaiser L, Bieber F, Garman RL.

Alzheimer Dis Assoc Disord. 2001 Oct-Dec;15(4):174-83. Erratum in: Alzheimer Dis Assoc Disord 2002 Jan-Mar;16(1):48.

PMID:
11723368
16.

Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.

Passmore AP, Bayer AJ, Steinhagen-Thiessen E.

J Neurol Sci. 2005 Mar 15;229-230:141-6. Epub 2005 Jan 6.

PMID:
15760632
17.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1. Review.

PMID:
23642576
18.

Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.

Fariello RG.

Funct Neurol. 1997 May-Aug;12(3-4):221-5. Review. No abstract available.

PMID:
9218984
19.

[Alzheimer drugs for mild cognitive impairment].

Fellgiebel A.

Neuropsychiatr. 2007;21(3):230-3. German.

PMID:
17915184
20.

Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment.

Small BJ, Gagnon E, Robinson B.

Geriatrics. 2007 Apr;62(4):19-23. Review.

PMID:
17408315
Items per page

Supplemental Content

Write to the Help Desk